

Date and Time: *Thursday 12th July 2012 (10.00-16.00)*

Minutes: Final

Guideline Development Group Meeting

Place: *Boardroom, National Clinical Guideline Centre (NCGC), 180 Great Portland Street, London W1W 5QZ*

Present: All present for notes 1-10 unless where stated)
 Campbell Cowan (Chair) (CC)
 Liz Avital (LA)
 Sara Buckner (SB)
 George Chung (GC)
 Matthew Fay (MF)
 David Fitzmaurice (DM)
 Lina Gulhane (LG)
 Clare Jones (CJ)
 Gregory Lip (GL)
 Clifford Mann (CM) (Present for notes 9 – 10)
 Nick Mills (NM)
 Vicki Pollit (VP)
 Eileen Porter (EP)
 Rebekah Schiff (RSf)
 Richard Schilling (RSg)

In attendance:

NICE Staff:	Sarah Dunsdon Barbara Meredith	(Present for notes 1 – 10) (Present for notes 1 – 7)
-------------	-----------------------------------	---

Observers:

NCGC Staff:	Martin Harker Juan Carlos Rejon	(Present for notes 8 – 9) (Present for notes 8 – 9)
-------------	------------------------------------	--

Notes

1. Welcome introductions and apologies

CC welcomed the group to the first meeting of this GDG. Apologies were received from Suzannah Power (SP). CC welcomed the observers to the group.

2. Working with NICE

SD gave an overview of NICE and its commissioning relationship with the NCGC. She explained the support available to the GDG throughout guideline development and the products that are expected to be produced.

3. The NCGC guideline programme and declarations of interest

LA explained the role of the NCGC and who the technical team are. She then gave details on declarations of interest (DOIs) and detailed the importance of them. The group then verbally declared their DOIs:

CC - Personal pecuniary interest: I participated in a meeting organised by Boehringer-Ingelheim in January 2012 to present the GRASP-AF data. I declined an honorarium for my participation, but my standard class rail fare to attend the meeting was reimbursed by B-I.
 Personal family interest: None.
 Non-personal pecuniary interest: Sponsorship of departmental and MDT meetings by various pharmaceutical companies to provide hospitality. I have no direct relations in the organisation of these meetings.

A research fellow in the electrophysiology Department in Leeds General Infirmary is partially funded from a research project undertaken in conjunction with St Jude Medical. The fellow does not work directly with me and I do not have managerial responsibility for electrophysiology services in the infirmary.

Personal non-pecuniary interest: I am the national clinical lead for AF for NHS Improvement. Our work has involved extensive campaigning to improve the uptake of anti-coagulation in patients with AF in accordance with NICE guidelines. I am on the Medical Advisory Committees of two patient organisations, Arrhythmia Alliance and Atrial Fibrillation Association.

GC - None declared.

MF - Non-personal pecuniary interest: Have received honoraria from Abbott, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi-Aventis within the last 12 months. These payments are not personally acquired but are paid to the Westcliffe Medical Practice partnership of which I am a partner.

1st July 2011 Bradford

7th July 2011 Hallam Stroke Meeting

7th July 2011 Education4health

7th July 2011 APPG on Anticoagulation

12th July 2011 Birmingham (AF course)

29th August to 2nd September European Cardiac Society funded by Bayer

8th September 2011 Bristol (Avon, Gloucestershire, Wiltshire CVD network (2 presentation)

9th September 2011 Bristol

16th September NHS-Improvement London

20th September 2011 Huddersfield

22nd September 2011 Uxbridge (BMS)

29th September 2011 Bradford

1st October 2011 Leeds

2nd October 2011 Birmingham (Heart Rhythm Congress Patient Day-STARS)

2nd October 2011 Birmingham (Heart Rhythm Congress Patient Day-AFA)

3rd October 2011 Birmingham (NHS-I at HRC)

3rd October 2011 Birmingham (Sanofi Aventis at HRC)

3rd October 2011 Birmingham (STARS scientific at HRC)

10th October 2011 Bolton for Greater Manchester and Cheshire CVN

11th October 2011 Windermere (DAWN 4S)

13th October 2011 Keighley

3rd November 2011 Telford (CVD Network)

9th November 2011 SPAF Academy Faculty Meeting (SPAF Academy is funded by BI)

16th November 2011 Uxbridge (BMS)

26th November 2011 Gerard's Cross (Daiichi Sankyo)

29th November 2011 Glasgow (NHS-I at the National Stroke Forum)

30th November 2011 Glasgow (BI symposium at the National Stroke Forum)

7th December 2011 Shipley (this was a local thing but presented the Einstein paper re Rivaroxaban in DVT)

9th December 2011 Leeds (Hepatology network)

15th December 2011 Ad Board Pfizer

20th December 2011 Ad Board Abbott

17th January 2012 Shipley

18th January 2012 BI Ad Board

20th January 2012 Birmingham (Bayer)

23rd-25th January 2012 Minneapolis (Medtronic Advisory Event)

2nd February 2012 Accrington CSNLC network 9th February 2012 York (RCGP)

9th February 2012 York (BMS/Pfizer)

15th March 2012 London SPAF Academy (2 presentation and launch of the Stop Start Campaign)

23rd March 2012 Ad Board with Pfizer

30th March 2012 Ad Board with BI

5th April 2012 London NHS-I

19th April 2012 Shipley

20th April 2012 Birmingham (AF course)

24th April 2012 London (BMJ Masterclass)

26th April 2012 Harrogate (Dermatology Specialist Group, this was about primary prevention but I do not know who sponsored the overall conference)

4th May 2012 Birmingham (Roche consensus meeting)

17th May 2012 Birmingham (Anticoagulation in Practice)

22nd May 2012 London (APPG on CVD Outcomes at the invitation of National Stroke Association)

31st May 2012 London DoH CVD Outcomes Strategy meeting

14th June 2012 Wakefield

26th June 2012 London (Hallam AF Meeting)

<p>28th June 2012 London (The Commissioning Show at the invitation of Roche) 10th July 2012 Colchester (East of England Cardiovascular Network) 11th July 2012 Bradford (Medicine Management Group)</p>
<p>DF - Personal pecuniary interest: I have received honoraria from various companies which may have an interest in this report, including Roche diagnostics, Leo Laboratories, Boehringer Ingelheim, Pfizer. 26-28 August 2011 attendance at European Society of Cardiology, funded by B-I. 7 September 2011 GP meeting, honorarium from B-I 8 September 2011 two GP meetings, honoraria from B-I 15 September 2011 GP meeting, honorarium from B-I. 5 December 2011 B-I advisory board regarding Dabigatran. 19 March 2012 Adviosry board for Pfizer regarding Apixaban 28 May 2012 Adviosry board for Pfizer regarding Apixaban. Non-personal pecuniary interest: The Department of Primary Care, University of Birmingham, have received educational grants from B-I and Roche Diagnostics UK over the last 12 months. Personal non-pecuniary interest: Medical advisor to Anticoagulation Europe (ACE). Chair of Anticoagulation in Practice (AiP)</p>
<p>GL – Personal pecuniary interest: I have served as a consultant: Sept 2011 – BI satellite, Venice Arrhythmia Oct 2011 – Bayer satellite, Eurothrombosis meeting Jan 2012 – BI CME meeting, Belfast March 2012 – Chaired advisory board for BMS/Pfizer March 2012 – Chaired advisory board for Daiichi-Sankyo April 2012 – BI satellite at World Congress of Cardiology, Dubai May 2012 – Advisory board for Roche May 2012 – BI lecture, British Cardiac Society June 2012 – Chaired advisory board for BMS/Pfizer July 2012 – Advisory board for Roche July 2012 – BI symposium at South Africa Heart meeting I have lectured in CPD/CME-accredited educational symposia for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi Aventis (Sanofi Aventis over 12 months ago). Lectures were mostly on AF management, AF in general or stroke prevention were only given in CME/CPD accredited programmes and used own slides. Non-personal pecuniary interest: My department has received unrestricted non-promotional educational grants for research from Bayer and Boehringer-Ingelheim.</p>
<p>CM - None declared.</p>
<p>NM - None declared.</p>
<p>EP - Personal non-pecuniary interest: All party parliamentary group on atrial fibrillation – submitted comments.</p>
<p>RSf - Personal non-pecuniary interest: Royal Society of Medicine talk on Top Tips in Atrial Fibrillation – April 2012.</p>
<p>RSg - Personal pecuniary interest: By date paid; 17 August 2011 honorarium from Touch Briefings for interview and article European Cardiology Vol 6, 9 March 2010. 30 August 2011 honorarium from Biosense Webster for Israel trip from 17-19 July. 2 September 2011 honorarium from Hansen for providing experience on Hansen robot (12 July 2011). 23 September 2011 reimbursement of travel expenses for 29 august ESC2011 in Paris form Daiichi-Sankyo. 10 November 2011 honorarium from St Jude Medical for Euro Japan (19-21 September). 17 November 2011 honorarium from APHRS for Japan 19-21 September trip. 28 November 2011 honoraria from BMJ for MC304/RS 29 November 2011 expenses for BMJ from 7 November 2011 14 December 2011 expenses from Biosense Webster for Israel trip 17-19 July 2011. 19 December 2011 honoraria from Hansen for lecturing at flexible Robotics Institute 9th November 2012. 20 December 2011 from Medtronic for Heart Rhythm Congress honorarium. 23 December 2011 expenses and honorarium from Daiichi-Sankyo for advisory board meeting. 20 February 2012Remiburesement flights to Australia for lecture tour 13-17 August 2012 from Conference Company of Australia (Australian cardiac society). 29 February 2012 honorarium from Pri-Med Educational Programmes LTD for advisory panel 26</p>

January 2012.

5 March 2012 honorarium teaching basic EP course September for European heart Rhythm Alliance.

6 March 2012 honorarium for MCZ16/RS from BMJ.

28 March 2012 reimbursement travel expenses from 24 January 2012 from RCPE.

29 March 2012 honorarium from royal college of GPs for Annual Primary Care conference 4-6 October.

2 April 2012 reimbursement travel expenses for master class on 19 March 2012 for BMJ.

18 May 2012 speaker at 4th practical session AFIB symposium Prague 14 March 2012 from Biosense Webster.

5 July 2012 honorarium plus expenses for EE Smart touch Round table meeting on 16 May 2011 from Biosense Webster.

12 July 2012 speaker at HRS symposium Boston on 10 May 2012 for

Non-personal pecuniary interest: My department currently receives the following research support:

AF Robotic Navigation – Hansen medical, CABANA – Mayo clinic (grant provided by St Jude Medical, Biosense Webster and NHLBI/NIH), CFE (Research Fellow WU) – Biosense Webster, Cardiology Research coordinator – Medtronic, CASTLE-AF – Biotronik, CRYO vs RFA – Medtronic, LIAISE – Medtronic, Prediction – Sorin Group, Research Fellow – Boston Scientific, Sponsored nurse – St Jude Medical, NOTICE-HF – Boston Scientific, PARADYM RF – Sorin Group, QUAD – St Jude Medical, PREFER AF – SSS International Clinical Research, Erase VT – Imperial College funded by Hansen medical.

Personal non-pecuniary interest: In presentations I consistently state that there is strong evidence for catheter ablation being superior to drugs for controlling symptomatic AF. I also state that there is no evidence to date for prognostic benefit to ablation. I also have publically stated that the evidence for the superiority of newer anticoagulants over warfarin in the western European population is not strong.

NCGC:

SB Personal pecuniary interest: I undertake consultancy work for medical reviewing for Kent, Surrey and Sussex Health Policy Support Unity. In the past year I have undertaken reviews on melatonin for sleep regulation in children with behavioural disorders (Nov-Feb 2012), removal of skin lesions (March 2012) and Insulin Degludec for Type 1 and 2 Diabetes (March 2012-August 2012). Funded by NHS.

Other NCGC staff: None declared.

NICE - None declared.

4. Patient and carer involvement

BM gave a presentation on the Patient and Public Involvement Programme at NICE.

5. Introduction to the scope

CC introduced the remit, population to be covered and the need for this guideline to be updated. He gave an overview of the key clinical areas and explained the areas that are not covered within the scope.

6. Searching the evidence

LG presented the role of information scientists in guideline development and discussed how to develop review questions using the PICO framework.

7. Evidence review process

SB presented the evidence review process including all stages of systematic reviewing.

8. Health economics process

VP gave an introduction to health economics in NICE guidelines and discussed cost-effectiveness and issues for the atrial fibrillation guideline.

9. Clinical and cost effectiveness review questions session

CJ introduced the draft review questions and explained that the technical team require information on the population, intervention, comparators and outcomes for each question. The GDG discussed the draft review questions.

10. Summary of next steps

CJ updated the GDG on future meeting dates.

Date, time and venue of the next meeting: Wednesday 12th September 2012, 10.00-16.00 Boardroom, NCGC 180 Great Portland Street, London, W1W 5QZ.